Showing posts with label Pathways. Show all posts
Showing posts with label Pathways. Show all posts

Tuesday, September 24, 2013

0 Costimulatory Pathways: Physiology and Potential Therapeutic Manipulation in Systemic Lupus Erythematosus




Clinical and Developmental Immunology Volume 2013 (2013), Article ID 245928, 12 pages http://dx.doi.org/10.1155/2013/245928

Review Article

Costimulatory Pathways: Physiology and Potential Therapeutic Manipulation in Systemic Lupus Erythematosus



Division of Rheumatology, Department of Medicine, University Medicine Cluster, Yong Loo Lin School of Medicine, National University of Singapore, Level 10, NUHS Tower Block, 1E Kent Ridge Road, Singapore 119228

Received 31 May 2013; Accepted 8 July 2013

Academic Editor: Guixiu Shi


Copyright © 2013 Nien Yee Kow and Anselm Mak. This is an open access article distributed under theCreative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Abstract


System lupus erythematosus (SLE) is an immune-complex-mediated autoimmune condition with protean immunological and clinical manifestation. While SLE has classically been advocated as a B-cell or T-cell disease, it is unlikely that a particular cell type is more pathologically predominant than the others. Indeed, SLE is characterized by an orchestrated interplay amongst different types of immunopathologically important cells participating in both innate and adaptive immunity including the dendritic cells, macrophages, neutrophils and lymphocytes, as well as traditional nonimmune cells such as endothelial, epithelial, and renal tubular cells. Amongst the antigen-presenting cells and lymphocytes, and between lymphocytes, the costimulatory pathways which involve mutual exchange of information and signalling play an essential role in initiating, perpetuating, and, eventually, attenuating the proinflammatory immune response. In this review, advances in the knowledge of established costimulatory pathways such as CD28/CTLA-4-CD80/86, ICOS-B7RP1, CD70-CD27, OX40-OX40L, and CD137-CD137L as well as their potential roles involved in the pathophysiology of SLE will be discussed. Attempts to target these costimulatory pathways therapeutically will pave more potential treatment avenues for patients with SLE. Preliminary laboratory and clinical evidence of the potential therapeutic value of manipulating these costimulatory pathways in SLE will also be discussed in this review.



Tuesday, September 17, 2013

0 Best strategies to implement clinical pathways in an emergency department setting. Study protocol in asthma and gastroenteriris.

Open Access


Study protocol


Best strategies to implement clinical pathways in an emergency department setting: study protocol for a cluster randomized controlled trial



Mona Jabbour, Janet Curran, Shannon D Scott, Astrid Guttman, Thomas Rotter, Francine M Ducharme, M Diane Lougheed, M Louise McNaughton-Filion, Amanda Newton, Mark Shafir, Alison Paprica, Terry Klassen, Monica Taljaard,Jeremy Grimshaw and David W Johnson










For all author emails, please log on.








Implementation Science 2013, 8:55 doi:10.1186/1748-5908-8-55

Published: 22 May 2013





Abstract (provisional)


Background


The clinical pathway is a tool that operationalizes best evidence recommendations and clinical practice guidelines in an accessible format for `point of care? management by multidisciplinary health teams in hospital settings. While high-quality, expert-developed clinical pathways have many potential benefits, their impact has been limited by variable implementation strategies and suboptimal research designs. Best strategies for implementing pathways into hospital settings remain unknown. This study will seek to develop and comprehensively evaluate best strategies for effective local implementation of externally developed expert clinical pathways. Design/methods We will develop a theory-based and knowledge user-informed intervention strategy to implement two pediatric clinical pathways: asthma and gastroenteritis. Using a balanced incomplete block design, we will randomize 16 community emergency departments to receive the intervention for one clinical pathway and serve as control for the alternate clinical pathway, thus conducting two cluster randomized controlled trials to evaluate this implementation intervention. A minimization procedure will be used to randomize sites. Intervention sites will receive a tailored strategy to support full clinical pathway implementation. We will evaluate implementation strategy effectiveness through measurement of relevant process and clinical outcomes. The primary process outcome will be the presence of an appropriately completed clinical pathway on the chart for relevant patients. Primary clinical outcomes for each clinical pathway include the following: Asthma?the proportion of asthmatic patients treated appropriately with corticosteroids in the emergency department and at discharge; and Gastroenteritis?the proportion of relevant patients appropriately treated with oral rehydration therapy. Data sources include chart audits, administrative databases, environmental scans, and qualitative interviews. We will also conduct an overall process evaluation to assess the implementation strategy and an economic analysis to evaluate implementation costs and benefits.

Discussion


This study will contribute to the body of evidence supporting effective strategies for clinical pathway implementation, and ultimately reducing the research to practice gaps by operationalizing best evidence care recommendations through effective use of clinical pathways. Trial registration ClinicalTrials.gov: NCT01815710






The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.



Monday, September 16, 2013

0 Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity




Thorax doi:10.1136/thoraxjnl-2012-202878




  • Chronic obstructive pulmonary disease



  • Original article



Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity


Open Access















  1. Dirkje S Postma1,2


+Author Affiliations




  1. 1Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands




  2. 2GRIAC (Groningen Research Institute for Asthma and COPD), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands




  3. 3Division of Computational Biomedicine, Department of medicine, Boston University School of Medicine, Boston, Massachusetts, USA




  4. 4Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands




  5. 5Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, The Netherlands




  6. 6Department of Respiratory Medicine, F5-259, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands




  7. 7Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts, USA





  1. Correspondence toDr M van den Berge, Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen 9700 RB, The Netherlands;m.van.den.berge@umcg.nl




  • Received 16 October 2012


  • Revised 4 June 2013


  • Accepted 30 June 2013


  • Published Online First 7 August 2013




Abstract



Background A core feature of chronic obstructive pulmonary disease (COPD) is the accelerated decline in forced expiratory volume in one second (FEV1). The recent Groningen and Leiden Universities study of Corticosteroids in Obstructive Lung Disease (GLUCOLD) study suggested that particular phenotypes of COPD benefit from fluticasone±salmeterol by reducing the rate of FEV1 decline, yet the underlying mechanisms are unknown.



Methods Whole-genome gene expression profiling using the Affymetrix Gene ST array (V.1.0) was performed on 221 bronchial biopsies available from 89 COPD patients at baseline and after 6 and 30 months of fluticasone±salmeterol and placebo treatment in GLUCOLD.



Results Linear mixed effects modelling revealed that the expression of 138 genes decreased, whereas the expression of 140 genes significantly upregulated after both 6 and 30 months of treatment with fluticasone±salmeterol versus placebo. A more pronounced treatment-induced change in the expression of 50 and 55 of these 278 genes was associated with a lower rate of decline in FEV1 and Saint George Respiratory Questionnaire, respectively. Genes decreasing with treatment were involved in pathways related to cell cycle, oxidative phosphorylation, epithelial cell signalling, p53 signalling and T cell signalling. Genes increasing with treatment were involved in pathways related to focal adhesion, gap junction and extracellular matrix deposition. Finally, the fluticasone-induced gene expression changes were enriched among genes that change in the airway epithelium in smokers with versus without COPD in an independent data set.



Conclusions The present study suggests that gene expression in biological pathways of COPD is dynamic with treatment and reflects disease activity. This study opens the gate to targeted and molecular phenotype-driven therapy of COPD.

This Article



This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:http://creativecommons.org/licenses/by-nc/3.0/